Fortis may be out of F&O if results delayed

The National Stock Exchange of India on Thursday said it will exclude Fortis Healthcare from the derivatives segment if the company fails to submit its financial results for the September and December quarter by March 1, reports Our Bureau.

So far, Fortis Healthcare has failed to submit its quarterly financial results for the September and December quarter, said NSE. Fortis has intimated to exchanges that its board will consider results for the two quarters in meeting on February 28.

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure

    AiMeD welcomes govt’s offer supporting development of advanced testing infrastructure

    Eluru police arrest five medical shop owners for illegal sale of Tramadol injections

    Eluru police arrest five medical shop owners for illegal sale of Tramadol injections

    KAISHA Pharma establishes Kaisha Pharma International in Italy

    KAISHA Pharma establishes Kaisha Pharma International in Italy

    Apollo Navi Mumbai launches geriatric oncology clinic

    Apollo Navi Mumbai launches geriatric oncology clinic

    Maharashtra FDA cancels licences of 62 pharma units, 141 chemist shops

    Maharashtra FDA cancels licences of 62 pharma units, 141 chemist shops

    Himachal DCA honoured with ‘Regulatory Excellence Award’ at iPHEX 2026

    Himachal DCA honoured with ‘Regulatory Excellence Award’ at iPHEX 2026